Allopregnanolone

The prototypical inhibitory neurosteroid and the endogenous molecule behind brexanolone (Zulresso); a potent GABA-A receptor positive allosteric modulator central to stress, reproductive and mood physiology.

As an endogenous molecule present throughout life, allopregnanolone is not intrinsically toxic, but its pharmaceutical forms carry meaningful risks. Brexanolone, the intravenous formulation, carries a boxed warning in the United States for excessive sedation and sudden loss of consciousness during infusion; it can be administered only in a certified healthcare setting under continuous monitoring through a Risk Evaluation and Mitigation Strategy program, and the standard course is a single continuous 60-hour infusion. The oral analog zuranolone commonly causes somnolence, dizziness and cognitive or psychomotor impairment sufficient to affect driving, and its labeling cautions against activities requiring full alertness.

A distinctive and clinically important feature of allopregnanolone pharmacology is a biphasic or inverse dose-response profile; while high concentrations are sedative and anxiolytic, low or moderate concentrations can paradoxically provoke anxiety, irritability and dysphoria in a susceptible subset of people, a phenomenon central to premenstrual dysphoric disorder.

Sustained exposure can produce tolerance and physical dependence, and abrupt withdrawal is associated with hyperexcitability linked to remodeling of GABA-A receptor subunits, notably an increase in alpha-4 containing receptors. Because the neurosteroid readily crosses into the brain and adds to other central depressants, combination with alcohol, benzodiazepines or opioids heightens the risk of dangerous sedation.

The sedative and anesthetic properties of steroids were first documented by Hans Selye in 1941, who observed that certain progesterone metabolites rapidly induced anesthesia, an effect far too fast to be explained by the classical genomic action of steroid hormones. The concept of the neurosteroid, a steroid synthesized de novo within the nervous system, was introduced by Etienne-Emile Baulieu in the early 1980s.

The specific identity of allopregnanolone as a potent modulator of the GABA-A receptor was established in 1986 by Maria Dorota Majewska and colleagues at the United States National Institute of Mental Health, who showed that progesterone metabolites act as barbiturate-like modulators of the GABA-chloride channel complex; Steven Paul and Robert Purdy subsequently formalized the neuroactive steroid framework and demonstrated that acute stress rapidly elevates brain allopregnanolone.

Synthetic congeners followed, including the anesthetic alphaxalone and the orally active analog ganaxolone. In the 2010s the biotechnology company Sage Therapeutics developed a solubilized formulation of allopregnanolone (SAGE-547, brexanolone) together with an oral analog (SAGE-217, zuranolone). Brexanolone received United States Food and Drug Administration approval in March 2019 as the first therapy indicated specifically for postpartum depression; ganaxolone (Ztalmy) was approved in 2022 for seizures associated with CDKL5 deficiency disorder, and zuranolone (Zurzuvae) was approved in 2023 for postpartum depression.

Within neuroscience, allopregnanolone is regarded as a landmark compound that validated the entire concept of neurosteroids and of rapid, non-genomic steroid signaling at ion channels. In clinical psychiatry its pharmaceutical form brexanolone was widely described as a breakthrough, offering antidepressant relief within days rather than the weeks required by serotonergic drugs and providing the first mechanism-specific treatment for postpartum depression.

Enthusiasm has been tempered by practical constraints; the 60-hour inpatient infusion, high cost and restricted-distribution requirements limited real-world uptake of brexanolone, and although the oral successor zuranolone improved convenience, United States regulators approved it only for postpartum depression after declining the broader major-depressive-disorder indication.

In nootropic and self-experimentation communities allopregnanolone itself is considered impractical because it is poorly absorbed orally and rapidly cleared; interest instead centers on its precursors such as pregnenolone and progesterone and on the molecule's value in explaining the calming effect of progesterone, the mechanism of premenstrual mood change, and the overlap between neurosteroid pharmacology and the actions of alcohol and benzodiazepines.